Clinical trials: Type 2 Diabetes Mellitus (T2DM)
Patient Satisfaction, Continuous Glucose Monitoring
Experience With the Use of Continuous Glucose Monitoring (CGM) Devices in People With Type 2 Diabetes Mellitus
Background: In recent years, diabetes management has evolved with the introduction of continuous glucose monitoring (CGM) devices.
- Conditions
- Patient Satisfaction, Continuous Glucose Monitoring, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- Glucocavi (NCT07019753)
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM
To evaluate the effect of the combination of chromium picolinate (600 μg Cr) + biotin (2 mg) versus placebo on glycosylated hemoglobin (HbA1c), lipid profiles (Total-C, HDL-C, LDL-C, TGs, TG/HDL ratio, etc), and pharmacoeconomic…
- Trial name
- NCT00289354
- Testing
- Chromium Picolinate (600 mcg Cr) + biotin (2 mg)
- Volunteers
- 600 people
- Sponsor
- Nutrition 21, Inc.
Type 2 Diabetes Mellitus (T2DM)
THE EFFECT OF BITTER ORANGE (CITRUS AURANTIUM) OIL AROMATHERAPY ON SLEEP QUALITY AND FATIGUE LEVELS
This study will be conducted to examine the effect of bitter orange oil inhalation aromatherapy on sleep quality and fatigue levels in patients with Type 2 Diabetes Mellitus (DM).
- Trial name
- NCT07756151
- Testing
- bitter orange oil group
- Volunteers
- 100 people
- Sponsor
- Uludag University
T2DM (Type 2 Diabetes Mellitus)
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone.
- Trial name
- HARMONY (NCT06415773)
- Testing
- HTD1801, Dapagliflozin
- Where
- 53 sites in China
- Volunteers
- 367 people
- Sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Type 2 Diabetes Mellitus (T2DM)
An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes
An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients with Type 2 Diabetes Primary Research Objective To evaluate the safety of Henagliflozin in Chinese patients with type 2 diabetes mellitus…
- Trial name
- NCT06959030
- Testing
- No Intervention: Observational Cohort
- Where
- 7 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital of Guangxi Medical University
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
The study is designed to demonstrate the short term efficacy and safety of vildagliptin 50 mg bid in patients with Type 2 Diabetes Mellitus inadequately controlled with Metformin.
- Trial name
- NCT01426802
- Testing
- vildagliptin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
T2DM
Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes
The intervention in this study consists of a 75-min intraduodenal infusion of an isotonic solution containing either of calcium chloride (CaCl2) or control (saline).
- Trial name
- NCT06942195
- Testing
- Ca-1000, Ca-500, Control
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- University of Adelaide
Type 2 Diabetes
IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics
This is a Phase I, first-in-human, randomised, double-blinded, placebo-and active-controlled study to assess the safety, tolerability, PK, PD, efficacy, and food-effect of IDG-16177 in healthy male subjects and patients with T2DM…
- Trial name
- NCT04982705
- Testing
- [Part 1.1] IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177
- Where
- Germany
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Type 2 Diabetes Mellitus (T2DM), Systemic Inflammation
Individualized Medical Nutrition Therapy in Adults With Type 2 Diabetes Mellitus
This study aims to investigate the effects of intensive medical nutrition therapy on blood sugar control, systemic inflammation, and gut barrier function in adults with type 2 diabetes mellitus.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Systemic Inflammation, Intestinal Permeability, Glycemic Control
- Trial name
- NCT07037212
- Testing
- Intensive Medical Nutrition Therapy (MNT), Standard Dietary Counseling
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Serap Balaban Barta
Diabetes Mellitus, Type 2
Chronic Effects of Two Aerobic-training Models Performed in Water and on Dry Land in Patients With Type 2 Diabetes Mellitus (T2DM).
The aim of this study was to analyse the acute and chronic effects of two aerobic-training models performed in water and on dry land on cardiorespiratory, functional, metabolic, hormonal and quality-of-life parameters in patients…
- Trial name
- NCT01956357
- Testing
- Aquatic exercise, Land Exercise
- Where
- Brazil
- Volunteers
- 35 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
NASH, NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled.
- Conditions
- NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2
- Trial name
- NCT04702490
- Testing
- MET409 Active, Empagliflozin
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Metacrine, Inc.
Diabetes Type 2
Janagliflozin Treat T2DM Monotherapy
The purpose of this study is to assess the effect of Janagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 24 weeks of treatment, and to assess the efficacy after 52 weeks of treatment, overall safety and…
- Trial name
- NCT03811548
- Testing
- Janagliflozin 25mg, Janagliflozin 50mg
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
T2DM (Type 2 Diabetes Mellitus), Fatty Liver
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, liraglutide, or…
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Fatty Liver, NAFLD
- Trial name
- ALT (NCT03233178)
- Testing
- Non-interventional
- Where
- Canada
- Volunteers
- 4,000 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Type 2 Diabetes
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.
- Trial name
- NCT02386982
- Testing
- HMS5552
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hua Medicine Limited
Type 2 Diabetes Mellitus
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks.
- Trial name
- NCT02526524
- Testing
- Met DR, Met IR
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 571 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Diabetes Mellitus Type 2 With Periodontal Disease
Using AR Dental Care Training System in HE on Periodontal Status, Blood Sugar Control and QoL in Patients With T2DM
The aim of this study was to evaluate the long-term effectiveness of an AR dental care training in health education on periodontal status, blood sugar control and quality of life in patients with poorly controlled type 2…
- Trial name
- NCT05941468
- Testing
- AR Dental Care Training System
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Type II Diabetes
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
- Trial name
- NCT00856908
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
AI-Predicted Disease Trajectories in Diabetes: A Retrospective Study
The study explores the utilization of artificial intelligence (AI) to predict disease progression trajectories in patients with diabetes.
- Trial name
- AI-TRYDIA (NCT06280729)
- Testing
- AI-Analyis
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- IRCCS San Raffaele